- Home
- WAT vs ICLR Comparison
WAT vs ICLR Comparison
Compare WAT & ICLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WAT
- ICLR
- Stock Information
- Founded
- WAT 1958
- ICLR 1990
- Country
- WAT United States
- ICLR Ireland
- Employees
- WAT N/A
- ICLR N/A
- Industry
- WAT Biotechnology: Laboratory Analytical Instruments
- ICLR Biotechnology: Commercial Physical & Biological Resarch
- Sector
- WAT Industrials
- ICLR Health Care
- Exchange
- WAT Nasdaq
- ICLR Nasdaq
- Market Cap
- WAT 17.0B
- ICLR 14.5B
- IPO Year
- WAT 1995
- ICLR 1998
- Fundamental
- Price
- WAT $291.56
- ICLR $175.84
- Analyst Decision
- WAT Hold
- ICLR Buy
- Analyst Count
- WAT 14
- ICLR 13
- Target Price
- WAT $374.07
- ICLR $211.92
- AVG Volume (30 Days)
- WAT 1.0M
- ICLR 1.7M
- Earning Date
- WAT 08-04-2025
- ICLR 07-23-2025
- Dividend Yield
- WAT N/A
- ICLR N/A
- EPS Growth
- WAT 10.77
- ICLR 13.11
- EPS
- WAT 11.09
- ICLR 9.73
- Revenue
- WAT $3,046,056,000.00
- ICLR $8,089,820,000.00
- Revenue This Year
- WAT $6.27
- ICLR N/A
- Revenue Next Year
- WAT $6.49
- ICLR $1.72
- P/E Ratio
- WAT $26.30
- ICLR $18.06
- Revenue Growth
- WAT 5.89
- ICLR N/A
- 52 Week Low
- WAT $275.05
- ICLR $125.10
- 52 Week High
- WAT $423.56
- ICLR $328.35
- Technical
- Relative Strength Index (RSI)
- WAT 44.31
- ICLR 59.78
- Support Level
- WAT $278.49
- ICLR $154.97
- Resistance Level
- WAT $296.89
- ICLR $176.81
- Average True Range (ATR)
- WAT 7.48
- ICLR 6.28
- MACD
- WAT 2.68
- ICLR 0.00
- Stochastic Oscillator
- WAT 53.76
- ICLR 61.13
About WAT Waters Corporation
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2024, Waters generated 58% from biopharmaceutical customers, 31% from industrial clients, and 11% from academic/government institutions. In early 2026, Waters plans to merge with BD's life science and diagnostics business, which will substantially change those concentrations. Waters will wind up with more concentration in diagnostics (versus none now) and discovery-related life science tools.
About ICLR ICON plc
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.